The drug has been shown to be effective at preventing HIV infection but does not cure an existing HIV infection.

Lenacapavir, a preventive HIV drug, could become accessible in low-income countries by 2026. Efforts spearheaded by global ...

While the efficacy of twice-yearly subcutaneous lenacapavir for HIV prevention has previously been demonstrated in cisgender ...

Science magazine has chosen twice-yearly lenacapavir PrEP as its 2024 Breakthrough of the Year, recognizing it as a ...

By 2025, a new HIV preventive drug, lenacapavir, could be available to the world's poorest regions. The Global Fund aims to ...

A new injectable drug for HIV prevention, lenacapavir, is being hailed as a potential game-changer in the fight against the ...

Investors are bullish on Gilead as the stock surges on successful launches and strong financial health, offering potential ...

That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...

The post appears to reference the drug lenacapavir, which reportedly can cost around $40,000 annually in the U.S. and is administered in twice-yearly doses. While the drug appears to be effective ...

A new long-acting preventive HIV drug could reach the world’s poorest countries by the end of 2025 or early 2026, a global ...

One study revealed that injection of the medication lenacapavir every six months could greatly reduce the risk for HIV infection among at-risk individuals. Human immunodeficiency virus (HIV ...